Baynes Roy D. 4

What Happened Roy D. Baynes, a non-employee director of Travere Therapeutics, received equity awards on 2026-05-19 totaling 16,000 shares: 4,000 shares issued outright and 12,000 shares issued as a derivative award (e.g., RSU-type). Both awards were granted at $0.00 per share (total reported value $0) under the company’s director compensation program. This was an award/grant (code A) — not a purchase or sale — and represents routine director compensation rather than an open-market trade.

Key Details

• Transaction date: 2026-05-19; Form 4 filed 2026-05-21 (timely filing).
• Price: $0.00 per share; total reported value $0.
• Award breakdown: 4,000 shares (stock) + 12,000 derivative shares (RSU-like).
• Vesting: Awards vest over one year (footnote F2).
• Plan/Program: Automatic equity grant under the 2018 Equity Incentive Plan for non-employee directors (footnote F1).
• Filing accession: 0001680739-26-000012.
• Shares owned after transaction: not specified in the provided filing excerpt.

Context Director awards like this are common non-cash compensation for board service and are generally considered routine. Because these are grants that vest over time (not open-market purchases or sales), they do not directly signal immediate insider buying or selling of stock.